相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents
Jane Merlevede et al.
NATURE COMMUNICATIONS (2016)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia
Jeffery M. Klco et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related Clonal Hemopoiesis
Thomas McKerrell et al.
CELL REPORTS (2015)
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Rafael Bejar et al.
BLOOD (2014)
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
F. Traina et al.
LEUKEMIA (2014)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T. Haferlach et al.
LEUKEMIA (2014)
Age-related mutations associated with clonal hematopoietic expansion and malignancies
Mingchao Xie et al.
NATURE MEDICINE (2014)
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Giulio Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
Steven D. Gore et al.
HAEMATOLOGICA (2013)
Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
Jesus F. San-Miguel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
C. Craddock et al.
LEUKEMIA (2013)
Clonal diversity of recurrently mutated genes in myelodysplastic syndromes
M. J. Walter et al.
LEUKEMIA (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations
Britta Will et al.
BLOOD (2012)
The Origin and Evolution of Mutations in Acute Myeloid Leukemia
John S. Welch et al.
CELL (2012)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
K. H. Metzeler et al.
LEUKEMIA (2012)
A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission
Y. Boumber et al.
LEUKEMIA (2012)
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Li Ding et al.
NATURE (2012)
Clonal Architecture of Secondary Acute Myeloid Leukemia
Matthew J. Walter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes
Lewis R. Silverman et al.
CANCER (2011)
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Michael Luebbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
R. Itzykson et al.
LEUKEMIA (2011)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
Amanda F. Cashen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
Peter Atadja
CANCER LETTERS (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
